Protease inhibitor monotherapy for long-term management of HIV infection: A randomised, controlled, open-label, non-inferiority trial
- Paton, Nicholas I.
- Stöhr, Wolfgang
- Arenas-Pinto, Alejandro
- Fisher, Martin
- Williams, Ian
- Johnson, Margaret
- Orkin, Chloe
- Chen, Fabian
- Lee, Vincent
- Winston, Alan
- Gompels, Mark
- Fox, Julie
- Scott, Karen
- Dunn, David T.
- Fisher, M.
- Clarke, A.
- Hadley, W.
- Stacey, D.
- Johnson, M.
- Byrne, P.
- Williams, I.
- De Esteban, N.
- Pellegrino, P.
- Haddow, L.
- Arenas-Pinto, A.
- Orkin, C.
- Hand, J.
- De Souza, C.
- Murthen, L.
- Crawford-Jones, A.
- Chen, F.
DOIAbstract
Background: Standard-of-care antiretroviral therapy (ART) uses a combination of drugs deemed essential to minimise treatment failure and drug resistance. Protease inhibitors are potent, with a high genetic barrier to resistance, and have potential use as monotherapy after viral load suppression is achieved with combination treatment. We aimed to assess clinical risks and benefi ts of protease inhibitor monotherapy in long-term clinical use: in particular, the eff ect on drug resistance and future treatment options. Methods In this pragmatic, parallel-group, randomised, controlled, open-label, non-inferiority trial, we enrolled adults (=18 years of age) positive for HIV attending 43 public sector treatment centres in the UK who had suppresse...
Add to ORKG